3 active not recruiting, 3 terminated, 2 withdrawn, 1 no longer available. 7 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 3, Terminated 2, Withdrawn 2 |
| Phase 2 | 5 | Terminated 3, Active not recruiting 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Rivogenlecleucel: new trials by email Literature Review of Rivogenlecleucel trials Research Report on Rivogenlecleucel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Terminated | Bellicum Pharmaceuticals | 1 | 2018-12-27 | 2023-09-29 |
| Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant BPX-501 T cells, rimiducid - Hematologic Malignancy | Phase 1 | Active not recruiting | Bellicum Pharmaceuticals | 15 | 2018-02-01 | 2022-07-12 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Rimiducid, rivogenlecleucel - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2017-01-01 | 2023-09-26 |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT rivogenlecleucel, Rimiducid - Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Bellicum Pharmaceuticals | 2016-05-01 | 2020-10-05 | |
| Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Active not recruiting | Bellicum Pharmaceuticals | 120 | 2014-04-01 | 2022-07-12 |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2014-04-01 | 2023-09-29 |
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant BPX-501 dose 1, Rimiducid, BPX-501 dose 2 - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Bellicum Pharmaceuticals | 36 | 2013-03-01 | 2022-07-12 |
| BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study rivogenlecleucel, rimiducid - Hurler Syndrome, Inherited Metabolic Disorder | No longer available | Bellicum Pharmaceuticals | 2020-10-05 |
Myelodysplastic Syndromes (8) · Leukemia, Myeloid, Acute (6) · Hematologic Neoplasms (5) · Leukemia (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Anemia, Aplastic (3) · Cytopenia (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Primary Immunodeficiency Diseases (3) · Anemia (2) · Anemia, Diamond-Blackfan (2) · Anemia, Sickle Cell (2) · Fanconi Anemia (2) · Hemoglobinopathies (2)
Bellicum Pharmaceuticals (8) · Fred Hutchinson Cancer Center (1)
United States (5) · Italy (3) · United Kingdom (1)
Elizabeth Krakow (1)
P30CA015704 (1)